219 related articles for article (PubMed ID: 36162696)
21. [Therapeutic advances of nuclear medicine in oncology].
Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
[TBL] [Abstract][Full Text] [Related]
22. Hybrid Protein Nano-Reactors Enable Simultaneous Increments of Tumor Oxygenation and Iodine-131 Delivery for Enhanced Radionuclide Therapy.
Chen J; Liang C; Song X; Yi X; Yang K; Feng L; Liu Z
Small; 2019 Nov; 15(46):e1903628. PubMed ID: 31577387
[TBL] [Abstract][Full Text] [Related]
23. Targeted radionuclide therapy directed to the tumor phenotypes: A dosimetric approach using MC simulations.
Borbinha J; Ferreira P; Costa D; Vaz P; Di Maria S
Appl Radiat Isot; 2023 Feb; 192():110569. PubMed ID: 36436229
[TBL] [Abstract][Full Text] [Related]
24. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
25. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer.
Dwyer RM; Schatz SM; Bergert ER; Myers RM; Harvey ME; Classic KL; Blanco MC; Frisk CS; Marler RJ; Davis BJ; O'Connor MK; Russell SJ; Morris JC
Mol Ther; 2005 Nov; 12(5):835-41. PubMed ID: 16054438
[TBL] [Abstract][Full Text] [Related]
26. Targeted radionuclide therapy: frontiers in theranostics.
Gallivanone F; Valente M; Savi A; Canevari C; Castiglioni I
Front Biosci (Landmark Ed); 2017 Jun; 22(10):1750-1759. PubMed ID: 28410143
[TBL] [Abstract][Full Text] [Related]
27. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy.
Shen DH; Marsee DK; Schaap J; Yang W; Cho JY; Hinkle G; Nagaraja HN; Kloos RT; Barth RF; Jhiang SM
Gene Ther; 2004 Jan; 11(2):161-9. PubMed ID: 14712300
[TBL] [Abstract][Full Text] [Related]
28. Preclinical in vivo cancer, straightway to patients?
de Jong M; Mather S; Maina T
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):145-152. PubMed ID: 28347131
[TBL] [Abstract][Full Text] [Related]
29. Clinical Pharmacology of Radiotheranostics in Oncology.
Te Beek ET; Burggraaf J; Teunissen JJM; Vriens D
Clin Pharmacol Ther; 2023 Feb; 113(2):260-274. PubMed ID: 35373336
[TBL] [Abstract][Full Text] [Related]
30. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
Jadvar H
AJR Am J Roentgenol; 2017 Aug; 209(2):277-288. PubMed ID: 28463538
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
32. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
33. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Timmermand OV; Tran TA; Strand SE; Axelsson J
J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
[TBL] [Abstract][Full Text] [Related]
34. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the development of
Munekane M; Fuchigami T; Ogawa K
Anal Sci; 2024 May; 40(5):803-826. PubMed ID: 38564087
[TBL] [Abstract][Full Text] [Related]
36. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.
Lassmann M; Hänscheid H; Chiesa C; Hindorf C; Flux G; Luster M;
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1405-12. PubMed ID: 18491092
[TBL] [Abstract][Full Text] [Related]
37. Prodrugs in site-selective delivery of radiopharmaceuticals.
Baranowska-Kortylewicz J; Kortylewicz ZP; Hoffman D; Dalrymple GV
Q J Nucl Med; 1997 Jun; 41(2):127-39. PubMed ID: 9203852
[TBL] [Abstract][Full Text] [Related]
38. Personalized & Precision Medicine in Cancer: A Theranostic Approach.
Choudhury P; Gupta M
Curr Radiopharm; 2017 Nov; 10(3):166-170. PubMed ID: 28758574
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic nuclear medicine in pediatric malignancy.
Schmidt M; Baum RP; Simon T; Howman-Giles R
Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):411-28. PubMed ID: 20823809
[TBL] [Abstract][Full Text] [Related]
40. Radiopeptides for Imaging and Therapy: A Radiant Future.
Chatalic KL; Kwekkeboom DJ; de Jong M
J Nucl Med; 2015 Dec; 56(12):1809-12. PubMed ID: 26514175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
